A recent study posted to medRxiv* preprint server reported a novel form of post-acute coronavirus disease 2019 (COVID-19) syndrome in children. Study: Acute tubulointerstitial nephritis with or ...

The use of existing guidelines for pediatric treatment varies significantly among sites, a new study has found. The study findingssuggest wide variation exists in the medications prescribed to treat ...

The US Food and Drug Administration (FDA) has approved belimumab (Benlysta) for treating active lupus nephritis (LN) in children aged 5–17 years. The drug can now be used to treat adult and pediatric ...

MMF induction is a viable alternative to cyclophosphamide for treating mixed proliferative lupus nephritis in children. Oral mycophenolate mofetil (MMF) is as effective as intravenous cyclophosphamide ...

In children with lupus nephritis, neurological manifestations at the time of kidney biopsy, age, and eGFR predicted greater risk of CKD progression. Investigators have identified predictors of chronic ...

A new study found that people who were diagnosed with lupus nephritis (LN) during childhood tend to have abnormal short-term kidney outcomes, especially if they are male and were diagnosed at an older ...

Please provide your email address to receive an email when new articles are posted on . Children treated with belimumab were more likely to achieve primary efficacy renal response vs. standard ...

Benlysta is a human monoclonal antibody that was approved for the treatment of lupus in adults by the U.S. Food and Drug Administration (FDA) in 2011 and for lupus nephritis in adults in 2020.

A sick child taking medication Real-world data on use of RAAS inhibitors can be used to support future pragmatic studies to optimize management of childhood-onset SLE, according to investigators.

With this approval, pediatric patients aged five years and older with active lupus nephritis will have a first-of-its-kind treatment option for at-home administration. PHILADELPHIA--(BUSINESS WIRE)-- ...